Diabetes Drug Pricing Vaccines 
STAT
AUGUST 22, 2023
The Food and Drug Administration approved a Pfizer vaccine that aims to protect newborns against RSV by vaccinating pregnant people, STAT tells us. The vaccine, marketed as Abrysvo, previously won approval for adults over the age of 60. Continue to STAT+ to read the full story…
STAT
MAY 20, 2024
For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. Sanders (I-Vt.)
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
OCTOBER 8, 2024
Food and Drug Administration for a “reckless and arbitrary” decision to remove a widely prescribed Eli Lilly drug for combating diabetes and obesity from an official shortages list , STAT tells us. In the late 1990s, the FDA raised concerns the vaccine lost potency toward the end of its 24-month shelf life.
STAT
JULY 6, 2023
Advertisements eviscerating and glorifying pharmacy benefit managers have been around for years, but have intensified over the past three months as Congress scrutinizes the role these middlemen play in shaping high prescription drug prices , STAT tells us.
Pharmaceutical Technology
DECEMBER 20, 2022
This downturn in market cap was attributed to a decline in the demand for Covid-19 vaccines and therapies. The growing competition from generic drugs presents challenges for the top 20 players placing pressure on drug prices. billion for Q3, according to GlobalData’s Drugs Database. trillion in Q2 2022 to $3.14
pharmaphorum
APRIL 27, 2022
The reputation of COVID-19 vaccine makers understandably soared early on, as clinical trials were started and completed in record time, giving hopes to millions of people in lockdown. Among individuals not vaccinated by choice, internet searches ranked as the number one source. Working on a diabetes drug?
Pharmaceutical Technology
MAY 16, 2023
increase in market capitalisation over Q1 2023, fuelled by its robust portfolio of diabetes and obesity treatments – in particular, its line of glucagon-like peptide 1 receptor agonist (GLP-1) Type 2 diabetes drugs Ozempic, Rybelsus and Victoza. Novo Nordisk reported an 18.2%
Expert insights. Personalized for you.
245 
Let's personalize your content